XENE

Xenon Pharmaceuticals

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$190.9M

Burn Rate (Qtr)

-$8.9M

Company Profile

XENON® (NASDAQ: XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

XEN496 (Potassium Channel Modulator)

Orphan Pediatric Epilepsy

Phase 3 (Initiation)

December 2020

XEN007 (Calcium Channel Inhibitor)

Childhood Absence Epilepsy

Phase 2 (Top-line Data)

Middle of 2021

XEN1101 (Potassium Channel Modulator)

Adult Focal Epilepsy

Phase 2 (Top-line Data)

Q3 2021

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon